| Vizz (U.S.N.L.M.) | |||
|---|---|---|---|
| Dosing (presbyopia) | 1 drop in each eye, wait 2 minutes, then a second drop in each eye once daily from the same single-dose vial |
||
| Chem Specs | (aceclidine ophthalmic solution) 1.44% Vials contain 1.75% aceclidine hydrochloride by weight which yields free base content of 1.44% aceclidine. |
||
| Quantities | carton of 25 single-dose vials (5 pouches × five vials of 0.4 mL each) | ||
| Cost | |||
| Class | Cholinergic muscarinic receptor agonist. | ||
| Action | Predominately pupil selective miotic. | ||
| Usage | Indicated for the treatment of presbyopia in adults. Maximum miosis typically occurs within 30 minutes, lasting between 5 and 10 hrs. |
||
| Warnings | Warn patients about hazard of reduced vision with night driving or other situations involving reduced illumination. No cases of retinal detachment have been reported with aceclidine ophthalmic solution in clinical trials to date, but retinal detachment remains a theoretical risk. The FDA states that Iris - Lens synechiae may be exacerbated in patients with a history of iritis. |
||
| Contraindications | Hypersensitivity to any ingredient or excipients. | ||
| Pediatric use | n/a | ||
| Pregnancy | There are no adequate and well controlled studies of VIZZ administration in pregnant women. Administration of aceclidine to pregnant rats and rabbits throughout organogenesis and lactation did not produce adverse maternal, fetal or neonatal effects at clinically relevant doses. |
||
| Unpreserved. | |||